Zika Virus Testing Market
ELISA Zika Virus Testings are Highly Preferred by Physicians. FMI Unveils Latest Trends in over 30 Countries with Potentially Greater Opportunities.
Zika Virus Testing Market By Test Type, End-user & Region – Forecast 2023–2033
Zika Virus Testing Market Outlook
FMI forecasts the global Zika virus testing market is likely to grow from US$ 4.9 Mn in 2023 to US$ 6.8 Mn by 2033. During this forecast period, the market is expected to exhibit a CAGR of 3.4%. Key reason fueling the growing consumption of Zika virus testing over the projection period is the growing incidence of Zika virus infection.
Since the dawn of the 21st century, the global healthcare community has been wrestling with countless epidemic outbreaks. This has significantly stretched existing infrastructure capabilities. Amongst all the epidemics faced today, viral infections have acquired the topmost position like the Severe Acute Respiratory Syndrome (SARS), Chikungunya, Swine Flu, and Zika Virus.
Demand for testing for Zika virus infections is growing by several important variables like the increased emergency authorization of POCT testing. The quick technological improvements and enhanced R&D in the domain of Zika virus RNA therapy are propelling the Zika virus therapeutics market.
Fortunately, numerous technological advances in diagnostic methods for Zika virus infection has enabled the healthcare industry to develop effective diagnostic and treatment. This leads to the introduction of highly advanced testing mechanisms. Viral isolation and a number of methods of detection of viral antigens, nucleic acids, and antibodies are at the core repertoire of techniques used for laboratory testing for Zika virus.
Let us know your requirement to get
100% FREE customization
Technological Advancements are Creating Massive Opportunities for the Market Players
Healthcare providers are increasing leaning towards ELISA and IgG/IgA whole-blood testing for diagnosis of acute Zika virus mechanisms. The major reason behind this is their high throughput rates and enhanced accuracy degree. Prominent Zika virus testing players seek to leverage collaborations with government agencies and private laboratories to accelerate their research and development prospects.
The Zika virus testing market is being driven by the availability of serology kits for the qualitative diagnosis of infection. Its purpose is to detect the presence of IgM antibodies created by the body's natural immune system after exposure to the Zika virus. It is commonly used for Zika diagnostic testing in the US. During the projected period, these elements are likely to boost Zika virus (ZIKV) diagnostics market.
Prominent laboratories are investing their funds in developing immunoglobulin testing and enzyme-linked immunosorbent assay (ELISA). Players such as LabCorp are at the forefront of the Zika virus testing market. They are offering the Aptima® Zika Virus Assay and the ZIKV DetectTM IgM Capture ELISA. These were authorized for emergency use initially. Such developments are further widening growth prospects in the future.
|
Attributes |
Details |
|
Zika Virus Testing Market Base Year Value (2022) |
US$ 4.7 Mn |
|
Zika Virus Testing Market Value (2023) |
US$ 4.9 Mn |
|
Zika Virus Testing Market Absolute Dollar Growth (US$ Mn/Bn) |
US$ 1.9 Mn |
|
Zika Virus Testing Market Expected Value (2033) |
US$ 6.8 Mn |
|
Zika Virus Testing Market Projected CAGR (2023-2033) |
3.4% |
How do the Historical Projections and Future Outlook Compare?
|
Historical CAGR (2017-2022) |
Forecast CAGR (2023-2033) |
|
2.7% |
3.4% |
According to Future Market Insights, the Zika virus testing market experienced slow-paced growth, registering a CAGR of over 2.7% until 2022. Key factors driving the market expansion is the intervention of national governments and international organizations like UNICEF in low-income developing regions. Additionally, the 2016 Zika virus epidemic has greatly aided the Zika virus testing market growth.
The market surpassed US$ 4.7 Mn in value as government initiatives to contain the virus’s spread resulted in massive awareness campaigns. This has accelerated the Zika virus (ZIKV) diagnostics market. Governmental and non-governmental efforts are unceasing in terms of discovering possible new breakthroughs in the future.
Short Term (2023 to 2026): As the intensity of the epidemic has waned, the incidence of testing has significantly dwindled. The development of the market is likely to be aided by elements like the scientific developments in Zika virus testing.
Medium Term (2026-2029): Diagnostic testing is expected to enter a new phase with the advent of constant viral pandemic and epidemic outbreaks. This is prompting clinicians and healthcare stakeholders to introduce highly advanced and precise testing solutions to ward of such threats.
Long Term (2029-2033): Infection with the Zika virus (ZIKV) is well recognized to be widespread throughout Southeast Asia and Africa. To lessen the morality, these nations are likely to improve their testing infrastructure for mosquito-borne public health problems.
The ever exploding frequencies of viral epidemics has put the global healthcare fraternity at the cusp of significant technological revolutions. This has boded well for the market for Zika virus test. On the back of these factors, sales in the Zika virus testing market are likely to increase reaching a valuation of US$ 4.9 Mn in 2023 and US$ 6.8 Mn by 2033.
| 2022 | US$ 4.7 Mn |
| 2023 | US$ 4.9 Mn |
| 2033 | US$ 6.8 Mn |
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystComparative Analysis of Adjacent Zika Virus Testing Markets
Zika Virus Testing Market:
|
Differentiating Aspects |
Zika Virus Testing Market |
|
CAGR (2023-2033) |
3.4% |
|
Market Valuation in 2023 |
US$ 4.9 Mn |
|
Projected Market Value in 2033 |
US$ 6.8 Mn |
|
Growth Factors |
Favorable government endeavors to manufacture advanced virus detection tests |
|
Opportunities |
Invention of POC diagnostics that provide results quickly |
|
Key Trends |
Response measures for the Zika outbreak are undertaken by organizations including the WHO, PAHO, and UNICEF. |
Zika Virus Therapeutics Market:
|
Differentiating Aspects |
Zika Virus Therapeutics Market |
|
CAGR (2023-2033) |
5.6% |
|
Market Valuation in 2023 |
US$ 19.69 Bn |
|
Projected Market Value in 2033 |
US$ 33.95 Bn |
|
Growth Factors |
Growing necessity to stop the spreading of this hazardous virus |
|
Opportunities |
The invention of vaccinations to combat it with the help of latest clinical improvement |
|
Key Trends |
Invention of specific serology kits for diagnosing Zika virus infection |
Zika Virus Vaccine Market:
|
Differentiating Aspects |
Zika Virus Vaccine Market |
|
CAGR (2023-2033) |
5.2% |
|
Market Valuation in 2023 |
US$ 19.66 Bn |
|
Projected Market Value in 2033 |
US$ 32.65 Bn |
|
Growth Factors |
Growing public awareness to prevent the spread of the zika virus infection |
|
Opportunities |
High expenditure in R&D to discover potent vaccines against the zika virus |
|
Key Trends |
Increasing number of clinical trials involving humans. |
Why is Demand for Zika Virus Testing High for Pregnant Women?
Documented findings have established that the zika virus has a high possibility of being passed on from a pregnant woman to her fetus. Infection during pregnancy leads to microcephaly and other severe fetal brain defects. Additionally, it may result in neurodevelopmental abnormalities such as hearing and visual impairment, limited locomotion, seizures and other abnormalities.
Therefore, it has become imperative for women to undergo periodic screening for possible presence of the virus in their bloodstream. According to the World Health Organization, zika virus infection is also a trigger for Guillain-Barre syndrome, neuropathy and myelitis, particularly in adults and older children. Hence, it is highly advisable for women residing within zika intensive areas to undergo laboratory testing for Zika virus and other clinical care.
At the same time, clinicians are advocating a slew of preventive measures owing to the dearth of any vaccine or drug to treat the virus. As it is a vector borne disease, mostly through mosquitos, personal protection measures such as wearing light-colored clothing that covers as much of the body as possible. Furthermore, using physical barriers such as window screens and closed doors and windows and applying insect repellants are considered the best alternatives.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Key Challenges faced by the Zika Virus Testing Providers
A major factor impeding revenue growth of the zika virus testing market is the inefficiency of these tests in delivering results. While ELISA tests are said to provide relatively accurate results compared to IgG/IgM testing, yet companies are unable to deliver products owing to cross reactivity with other widely circulating virus strands such as Flavivirus, Dengue, Chikungunya and Japanese Encephalitis.
Furthermore, the outreach of zika virus testing is restricted to tropical regions, as these are the primary infection hotspots, thus restricting their growth scope. Fortunately, countries across the temperate regions are increasing uptake of various serological tests amid growing concerns of the epidemic’s spread by virtue of people frequenting tropical regions for tourism.
Regional Share in Zika Virus Testing Market
| Regions | North America |
| Countries | United States, Mexico |
| CAGR (2023-2033) | 2.6%, 2.2% |
| Regions | Europe |
| Countries | United Kingdom |
| CAGR (2023-2033) | 2.0% |
| Regions | Asia Pacific |
| Countries | Thailand |
| CAGR (2023-2033) | 2.4% |
| Regions | Latin America |
| Countries | Columbia |
| CAGR (2023-2033) | 3.4% |
FMI has taken into account the epidemiological profiles of each nation to analyze the differential algorithm for the Zika virus diagnosis. The Zika virus testing market in North America held the biggest market share in 2022. It is anticipated to expand at a significant CAGR throughout the assessment period to hold its dominance.
According to statistics from the WHO updated in February 2022, Zika transmission continues in a number of countries but has been most prevalent at low levels from 2018 to the present. An outbreak in developed and developing nations resulted from the subsequent viral transmission over the Asia Pacific region. Massive Zika virus breakouts have also occurred in Latin American and Asia-Pacific nations.
Top Countries Driving Zika Virus Testing Market Growth
What Prospects are in Store for the US Zika Virus Testing Market?
Presently, as of 2021, there have been no documented instances of local zika virus transmission across the US. However, overseas territories have registered 7 active cases through presumed local mosquito-borne transmission. This number represents an impressive reduction as compared to 2019 levels wherein 28 active cases were reported, 27 in travelers returning from affected areas and 1 from laboratory exposure.
This reduction in cases is majorly credited to numerous regulatory approaches to facilitate active viral case load testing since the past few years. For instance, in May 2019, the Food & Drug Administration authorized marketing of the ZIKV Detect 2.0 IgM Capture ELISA to detect Zika virus Immunoglobulin (IgM) antibodies in human blood. This was the first diagnostic test permitted by the FDA to be commercially available.
|
Attributes |
Details |
|
US Market Size (2033) |
US$ 111.6 Th |
|
US Market Absolute Dollar Growth (US$ Mn/Bn) |
US$ 25.1 Th |
|
CAGR % 2017 to 2022 |
2.2% |
|
CAGR % 2023 to End of Forecast(2033) |
2.6% |
Likewise, in July 2019, FDA cleared the ADVIA Center Zika test, making it the second major IgM antibody test to be commercially available. Earlier, this test was only permitted for emergency use by decree of the FDA’s emergency use authorization directive. Two other tests- the LIASION XL Zika Capture IgM Assay II and DPP Zika IgM Assay System were eventually granted approval subsequently. Attributed to these approvals, scope for the US Zika virus testing market is increasing manifold.
How did Puerto Rico Generate High Ground for Zika Virus Testing?
According to the Centers for Disease Control and Prevention (CDC), zika virus is a major factor for microcephaly and other severe birth defects in babies born to women infected with the virus. Women living in Puerto Rico are especially at high risk of zika virus exposure due to local mosquito-borne transmission.
Beginning in 2016, healthcare providers in Puerto Rico were under administrative orders to provide counseling on zika virus risk-reduction strategies, assess patients for possible zika virus exposure during prenatal care visits and conduct prenatal testing for Zika virus. Additionally, the Puerto Rico Department of Health (PRDH) and the CDC worked together to conduct a population-based survey of women who gave birth to a live infant from August to December 2016.
The Pregnancy Risk Assessment Monitoring System - Zika Postpartum Emergency Response (PRAMS-ZPER) survey asked mothers about their use of recommended measures to prevent zika virus infection and their interactions with healthcare providers during their pregnancy. Most respondents replied that they received prenatal care in the 1st trimester (91%), while more than seven out of ten considered their healthcare provider to be the best source of information about the virus. Hence, regular diagnostic tests are administered to them to periodically check for any infections.
Why is the Mexico Zika Virus Testing Market Measured Money-spinning?
An infected Aedes species mosquito is the main vector for the propagation of the Zika virus. Pregnancy-related contaminations leads to several birth idiosyncrasies. Prior to 2015, the Pan American Health Organization (PAHO) issued a warning about the first confirmed Zika virus infections in Brazil. Zika was previously found in Africa, Southeast Asia, and the Pacific Islands. Since then, the Zika virus has been found in several nations and areas of the Caribbean, Central America, South America, and 26 out of 32 states in Mexico.
|
Attributes |
Details |
|
Mexico Market Size (2033) |
US$ 261.3 Th |
|
Mexico Market Absolute Dollar Growth (US$ Mn/Bn) |
US$ 51.1Th |
|
CAGR % 2017 to 2022 |
2.0% |
|
CAGR % 2023 to End of Forecast(2033) |
2.2% |
Mexico confirmed 35 cases of the Zika virus infection in 2021, an increase from the 20 cases that were recorded in 2020. 2016 has more than 8,000 instances of Zika infections in the North American nations. US citizens, especially those of Mexican descent, travel to Mexico more often than any other country. This makes Zika preventative outreach and information a crucial aspect of the domestic approach. The expansion of blood donation screening utilizing individual donor NAAT tests to stop the spread of diseases linked to transfusions.
The Instituto Mexicano del Seguro Social conducted Zika virus test around 80% of expectant Mexican women with potential Zika virus infection. The institute found the virus in about 27.8% of the women it tests. Hence, players are likely to find opportunities when it comes to testing for Zika virus infections in Mexico. The risk of Zika virus outbreak is very high in this country.
What is the Algorithm for Zika Virus Diagnosis the Thailand Market?
Over the forecast period, the Asia-Pacific region is likely to hold a major share of the market. The major reason behind this is the rising prevalence of the ZIKV in the nations, particularly in Thailand.
Growing infectious research and government measures to improve the healthcare system is very high in Thailand. Besides, increased awareness of the Zika virus and the advantages of early identification, rising R&D spending, are contributing in global revenue.
|
Attributes |
Details |
|
Thailand Market Size (2033) |
US$ 28.2 Th |
|
Thailand Market Absolute Dollar Growth (US$ Mn/Bn) |
US$ 6.0 Th |
|
CAGR % 2017 to 2022 |
2.1% |
|
CAGR % 2023 to End of Forecast(2033) |
2.4% |
Since 2012, Thailand has documented ZIKV infections. According to a 2017 survey, approximately 70% of Thai people have ZIKV neutralizing antibodies. Antibodies against mosquito-borne Flaviviridae can cross-react with Togaviridae viruses, according to a study of febrile patients in Thailand.
Five cases of the Zika virus infection have been recorded by medical professionals in the UK, Germany, and Israel. These are the individuals who visited Thailand between March 16 and June 2, 2022. These tourists had visited several places of Thailand which implies that the Zika virus is still being disseminated widely in the country.
What is the Development Status quo for Zika Virus Testing Market in the Columbia?
65,726 instances of ZIKV have been recorded in Colombia in 2016, and 2485 (4%) of those cases had been verified. Overall, female patients had a reported incidence of ZIKV that was twice as high as male patients' in Colombia.
According to evaluations of Zika-affected women in Colombia, the infection is particularly harmful to women and is deeply connected to poverty. Another study found that mothers of children with congenital Zika disease felt guilty and had to bear uneven levels of childcare.
|
Attributes |
Details |
|
Columbia Market Size (2033) |
US$ 188.5 Th |
|
Columbia Market Absolute Dollar Growth (US$ Mn/Bn) |
US$ 53.6 Th |
|
CAGR % 2017 to 2022 |
3.0% |
|
CAGR % 2023 to End of Forecast(2033) |
3.4% |
Is Brazil Expected to Generate Revenue Streams for Prominent Players?
Prominent zika virus testing players are expected to find credible opportunities across the Brazilian Zika virus testing market market, given the fact it was the epicenter of the initial epidemic outbreak. The outbreak was first documented by the discovery of fetal microcephaly across northeastern Brazil in 2015. In view of the harmful consequence of microcephaly, in November 2015 the Ministry of Health declared a Public Health Emergency of National Concern.
To combat this menace, the Brazilian government introduced a massive nationwide operation to eliminate potential mosquito breeding sites and to educate the public about its role in combating spread of the disease. In the initial stages, health worker or members of the armed forces visited over 20 million homes, representing almost 30% of all the country’s private residences. Such unceasing efforts led to a nationwide improvement in the eradication efforts of the virus.
Presently, Brazilian authorities have taken crucial measures in a transparent and timely manner in line with the International Health Regulations, a legal instrument which is binding for all World Health Organization member states, for which the country has invested in purchasing essential materials such as laboratory reagents, insecticides and diagnostic kits. Moreover, the WHO is also assisting Brazil in strengthening integrated management of disease-carrying organisms in public health, including upscaling use of larvicides to inhibit breeding of the Aedes mosquitos, the main vectors responsible for the virus’ transmission.
What are the Major Zika Virus Testing Guidelines in the UK?
According to Public Health England (PHE), testing for zika virus is available only through the Rare and Imported Pathogens Laboratory (RIPL) at PHE Porton. RIPL provides medical and laboratory specialist services to the National Health Service and other healthcare providers, covering advice and diagnosis of a wide range of unusual bacterial and viral infections, including zika virus infection.
|
Attributes |
Details |
|
UK Market Size (2033) |
US$ 22.3 Th |
|
UK Market Absolute Dollar Growth (US$ Mn/Bn) |
US$ 4.0 Th |
|
CAGR % 2017 to 2022 |
1.2% |
|
CAGR % 2023 to End of Forecast(2033) |
2.0% |
As per UK law, zika virus infection is not a notifiable disease. Therefore, there is no statutory requirement to test for this infection if the result are expected to have a negligible impact on clinical management. Presently, testing services are inaccessible for asymptomatic individuals, including pregnant women, male travelers and couples who are attempting to conceive. Couples planning conception should be strongly advised to follow PHE guidance and delay conception for 3 months after return from a country or area with risk for zika, rather than pay for private zika tests that may not be fully validated for testing people who don’t have symptoms.
With regard to investigating patients with previously suspected infection cases, clinicians can undertake testing for any patient who has had a rash illness or other symptoms suggestive of zika virus infection within 2 weeks of leaving any country suspected of having an outbreak. In such a case, patients have to submit serum or urine samples with an appropriate request form. Additionally, semen samples may also be tested in case of conceiving parents.
Zika Virus Testing Market Segment
| Segment | Test Type |
| Attributes | ELISA Kits |
| CAGR % 2017 to 2022 | 2.7% |
| CAGR % 2023 to End of Forecast(2033) | 3.2% |
| Segment | End-user |
| Attributes | Hospitals and Clinics |
| CAGR % 2017 to 2022 | 2.2% |
| CAGR % 2023 to End of Forecast(2033) | 3.0% |
Why are ELISA based Tests Most Preferred?
By test type, ELISA-based zika virus testing is the most preferred, surpassing US$ 4 billion until 2020. ELISA tests are highly relied upon due to its high specificity and sensitivity. Additionally, they offer greater accuracy compared to other techniques such as radioimmunoassay (RIA) tests. Moreover, it does not require radioisotopes or costly radiation counters.
Simultaneously, demand for IgG/IgM testing is anticipated to remain equally strong, reaching US$ 26 million in valuation as of 2020. These tests have exhibited promising results due to minimal sample requirement and complications associated with their usage. These tests help in simultaneous detection and differentiation of the zika virus in human serum and plasma.
Demand for Testing Kits to Remain High across Hospitals and Clinics?
By end-user, zika virus testing is likely to be extensively carried out by hospitals and clinics. Hospitals often have more resources at their disposal, including finances for initiating new clinical trials, affordability of sophisticated lab equipment, and enhanced specimen storage capacities among other benefits.
At the same time, government/publicly funded testing programs have experienced a significant incline. For example, in 2016, the US Congress allocated US$ 1.1 billion in supplemental funding to combat the zika virus to the Department of Health and Human Services (HHS), out of which US$ 394 million was allocated to CDC, US$ 152 million to NIH and US$ 387 million towards the public health and emergency fund.
Why are the Developments by Startups Highly in demand?
Keeping in mind the endemic of Zika virus, startups are making several developments in their testing kits and tools. They are integrating latest technological and clinical advancements in their products. They are also collecting additional funds and investing them in their research and developments.
LSK Technologies - Canada
Seray içek and Yuxiu (Livia) Guo, both graduates of the University of Toronto, formed LSK Technologies Inc. (LSK) alongside Professor Keith Pardee. They created their portable testing tools called PLUM to assist overburdened healthcare systems in isolated Latin American towns. It is going to help them to deal with the Zika virus threat.
Kineta Inc, - United States
Kineta, Inc. is a biotechnology startup. The business creates innovative immunotherapies to tackle autoimmune conditions, viral infections, and chronic pain. It has received funding to carry out more Zika virus testing on its broad spectrum innate immune antivirals. The National Institute of Allergy and Infectious Disease (NIAID) is providing this additional funds. The main aim is to assess lead wide range antivirals in preclinical models of Zika virus infection.
Market Players are Testing their Ability by Offering Advanced Testing Tools
Prominent zika virus testing market players are majorly emphasizing on incorporating advanced testing approaches to provide faster turn-around times and quicker results. This helps clinicians suggest the appropriate treatment approach to infected patients. They also rely on strategic collaborations with various institutions and companies to widen their market presence.
EUROIMMUN US is a prominent zika virus test provider, offering the anti-zika virus ELISA and indirect immunofluorescence test (IFA) formats which allows for detection of specific antibodies (IgM and IgG) in the blood of those who may be infected. In 2017, the company entered an optional agreement with Roche Diagnostics in which the latter gained access to intellectual property in zika virus immunodiagnostics assigned to EUROIMMUN.
Similarly, Creative Diagnostics offers the Recombinant Zika Virus Envelope protein test which contains Histidine tags. The protein reacts with both IgG and IgM to provide the desired result. Its purity score ranks above 85%, available in 1 mg vials. It also offers the Recombinant Zika Virus NS1 protein test.
- In April 2021, Luminex Corporation has signed and acquisition agreement with DiaSorin S.p.A. wherein the latter has agreed to acquire the former. Luminex believes that this transaction will generate significant opportunities for both companies to gain access to broader assay portfolios, enhanced research tools and expanded support services. This collaboration will also drive new partnerships in the biopharmaceutical, academic and clinical spaces. Previously, the US FDA has granted Emergency Use Authorization (EUA) to Luminex Corporation for a multiplex nucleic acid test. It was intended to identify Zika virus RNA in individuals who may be at risk of infection using their blood serum, plasma, or urine.
- In March 2022, The International Arbovirus Project was started by the World Health Organization. Initiated by the World Health Organization, the Global Arbovirus Initiative Zika, Dengue, Yellow fever, Chikungunya, and other Arboviruses are currently posing a danger to public health around the globe. By assembling a coalition of important partners, this integrated program is likely to improve the coordination, communication, capacity-building, research, readiness, and reaction required to reduce the rising risk of epidemics caused by these illnesses.
As per FMI’s analysis, the following players operate within the global zika virus testing market:
- EUROIMMUN US Inc.
- Creative Diagnostics
- Quest Diagnostics
- Artron Laboratories Inc.
- RapiGEN Inc.
- GenBody Inc.
- JAJ International Inc.
- LumiQuick Diagnostics Inc.
- Biocan Diagnostics Inc.
- NECTAR LIFESCIENCES LTD.
- Luminex Corporation
- ARUP Laboratories
- Abbott Molecular Inc.
- Hologic
- Vela Diagnostics
Key Segments Covered
Test Type:
- Rapid IgG/IgM Test
- ELISA Test
End-User:
- Hospitals & Clinics
- Private Commercial Laboratories
- Government/Publicly Funded Programs
Region:
- North America & Europe (US, UK, Germany, Spain, France, Italy and Rest of Europe)
- Latin America (Brazil, Mexico, Colombia and Rest of LATAM)
- Central America (Costa Rica, Nicaragua, Guatemala and Rest of Central America)
- Caribbean (Puerto Rico and Rest of the Caribbean)
- South East Asia (Thailand, Singapore, Vietnam and Rest of South East Asia)
- Rest of the World (North Africa and South Africa)
Frequently Asked Questions
The global zika virus testing market is set to register credible gains through 2023 and beyond, registering a multi-billion dollar valuation amid extensive research and development to incorporate highly advanced diagnostic approaches which will help in timely detection and diagnosis of the virus
As per FMI’s report, bulk of all zika virus testing market is expected to occur across the tropical regions of the world, such as the Asian sub-continent, Caribbean and Central America respectively
ELISA based zika virus testing treatment will likely remain the most preferred approach in forthcoming years due to its immense promises in terms of higher accuracy and efficacy
EUROIMMUN US Inc., Creative Diagnostics, Quest Diagnostics, Artron Laboratories Inc., RapiGEN Inc., GenBody Inc., JAJ International Inc., LumiQuick Diagnostics Inc., Biocan Diagnostics Inc., NECTAR LIFESCIENCES LTD., Luminex Corporation, ARUP Laboratories, Abbott Molecular Inc., Hologic and Vela Diagnostics are some prominent regenerative medicine players profiled by FMI’s report
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Market Analysis 2017-2022 and Forecast, 2023-2033
4.1. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis, 2017-2022
4.2. Current and Future Market Size Value (US$ Mn) & Volume (Units) Projections, 2023-2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017-2022 and Forecast 2023-2033, By Test Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Test Type, 2017-2022
5.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Test Type, 2023-2033
5.3.1. Rapid IgG/IgM Test Kits
5.3.1.1. Strips
5.3.1.2. Cassettes
5.3.1.3. Cards
5.3.2. ELISA Kits
5.4. Y-o-Y Growth Trend Analysis By Test Type, 2017-2022
5.5. Absolute $ Opportunity Analysis By Test Type, 2023-2033
6. Global Market Analysis 2017-2022 and Forecast 2023-2033, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By End User, 2017-2022
6.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By End User, 2023-2033
6.3.1. Hospitals & Clinics
6.3.2. Private Commercial Laboratories
6.3.3. Government/ Publicly Funded Programs
6.4. Y-o-Y Growth Trend Analysis By End User, 2017-2022
6.5. Absolute $ Opportunity Analysis By End User, 2023-2033
7. Global Market Analysis 2017-2022 and Forecast 2023-2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Region, 2017-2022
7.3. Current Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Region, 2023-2033
7.3.1. North America & Europe
7.3.2. Latin America
7.3.3. Central America
7.3.4. Caribbean
7.3.5. South East Asia
7.3.6. Rest of the World
7.4. Market Attractiveness Analysis By Region
8. North America & Europe Market Analysis 2017-2022 and Forecast 2023-2033, By Country
8.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2022
8.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2023-2033
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Germany
8.2.1.3. France
8.2.1.4. Italy
8.2.1.5. U.K.
8.2.1.6. Spain
8.2.1.7. Rest of North America & Europe
8.2.2. By Test Type
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Test Type
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2017-2022 and Forecast 2023-2033, By Country
9.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2022
9.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2023-2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Colombia
9.2.1.4. Rest of Latin America
9.2.2. By Test Type
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Test Type
9.3.3. By End User
9.4. Key Takeaways
10. Central America Market Analysis 2017-2022 and Forecast 2023-2033, By Country
10.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2022
10.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2023-2033
10.2.1. By Country
10.2.1.1. Costa Rica
10.2.1.2. Nicaragua
10.2.1.3. Guatemala
10.2.1.4. Rest of Central America
10.2.2. By Test Type
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Test Type
10.3.3. By End User
10.4. Key Takeaways
11. Caribbean Market Analysis 2017-2022 and Forecast 2023-2033, By Country
11.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2022
11.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2023-2033
11.2.1. By Country
11.2.1.1. Puerto Rico
11.2.1.2. Rest of the Caribbean
11.2.2. By Test Type
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Test Type
11.3.3. By End User
11.4. Key Takeaways
12. South East Asia Market Analysis 2017-2022 and Forecast 2023-2033, By Country
12.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2022
12.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2023-2033
12.2.1. By Country
12.2.1.1. Thailand
12.2.1.2. Singapore
12.2.1.3. Vietnam
12.2.1.4. Rest of South East Asia
12.2.2. By Test Type
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Test Type
12.3.3. By End User
12.4. Key Takeaways
13. Rest of the World Market Analysis 2017-2022 and Forecast 2023-2033, By Country
13.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2022
13.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2023-2033
13.2.1. By Country
13.2.1.1. North Africa
13.2.1.2. South Africa
13.2.2. By Test Type
13.2.3. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Test Type
13.3.3. By End User
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. U.S.
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Test Type
14.1.2.2. By End User
14.2. Germany
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Test Type
14.2.2.2. By End User
14.3. France
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Test Type
14.3.2.2. By End User
14.4. Italy
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Test Type
14.4.2.2. By End User
14.5. U.K.
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Test Type
14.5.2.2. By End User
14.6. Spain
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Test Type
14.6.2.2. By End User
14.7. Brazil
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Test Type
14.7.2.2. By End User
14.8. Mexico
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Test Type
14.8.2.2. By End User
14.9. Colombia
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Test Type
14.9.2.2. By End User
14.10. Costa Rica
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Test Type
14.10.2.2. By End User
14.11. Nicaragua
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Test Type
14.11.2.2. By End User
14.12. Guatemala
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Test Type
14.12.2.2. By End User
14.13. Puerto Rico
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Test Type
14.13.2.2. By End User
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Test Type
14.14.2.2. By End User
14.15. Singapore
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Test Type
14.15.2.2. By End User
14.16. Vietnam
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Test Type
14.16.2.2. By End User
14.17. North Africa
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Test Type
14.17.2.2. By End User
14.18. South Africa
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Test Type
14.18.2.2. By End User
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Test Type
15.3.3. By End User
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. EUROIMMUN US Inc.
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.1.5.2. Product Strategy
16.1.1.5.3. Channel Strategy
16.1.2. Creative Diagnostics
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.2.5.2. Product Strategy
16.1.2.5.3. Channel Strategy
16.1.3. Quest Diagnostics
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.3.5.2. Product Strategy
16.1.3.5.3. Channel Strategy
16.1.4. Artron Laboratories Inc.
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.4.5.2. Product Strategy
16.1.4.5.3. Channel Strategy
16.1.5. RapiGEN Inc.
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.5.5.2. Product Strategy
16.1.5.5.3. Channel Strategy
16.1.6. GenBody Inc.
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.6.5.2. Product Strategy
16.1.6.5.3. Channel Strategy
16.1.7. JAJ International Inc.
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.7.5.2. Product Strategy
16.1.7.5.3. Channel Strategy
16.1.8. LumiQuick Diagnostics Inc.
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.8.5.2. Product Strategy
16.1.8.5.3. Channel Strategy
16.1.9. Biocan Diagnostics Inc.
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.9.5.2. Product Strategy
16.1.9.5.3. Channel Strategy
16.1.10. NECTAR LIFESCIENCES LTD.
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
16.1.10.5.2. Product Strategy
16.1.10.5.3. Channel Strategy
16.1.11. Luminex Corporation
16.1.11.1. Overview
16.1.11.2. Product Portfolio
16.1.11.3. Profitability by Market Segments
16.1.11.4. Sales Footprint
16.1.11.5. Strategy Overview
16.1.11.5.1. Marketing Strategy
16.1.11.5.2. Product Strategy
16.1.11.5.3. Channel Strategy
16.1.12. ARUP Laboratories
16.1.12.1. Overview
16.1.12.2. Product Portfolio
16.1.12.3. Profitability by Market Segments
16.1.12.4. Sales Footprint
16.1.12.5. Strategy Overview
16.1.12.5.1. Marketing Strategy
16.1.12.5.2. Product Strategy
16.1.12.5.3. Channel Strategy
16.1.13. Abbott Molecular Inc.
16.1.13.1. Overview
16.1.13.2. Product Portfolio
16.1.13.3. Profitability by Market Segments
16.1.13.4. Sales Footprint
16.1.13.5. Strategy Overview
16.1.13.5.1. Marketing Strategy
16.1.13.5.2. Product Strategy
16.1.13.5.3. Channel Strategy
16.1.14. Hologic
16.1.14.1. Overview
16.1.14.2. Product Portfolio
16.1.14.3. Profitability by Market Segments
16.1.14.4. Sales Footprint
16.1.14.5. Strategy Overview
16.1.14.5.1. Marketing Strategy
16.1.14.5.2. Product Strategy
16.1.14.5.3. Channel Strategy
16.1.15. Vela Diagnostics
16.1.15.1. Overview
16.1.15.2. Product Portfolio
16.1.15.3. Profitability by Market Segments
16.1.15.4. Sales Footprint
16.1.15.5. Strategy Overview
16.1.15.5.1. Marketing Strategy
16.1.15.5.2. Product Strategy
16.1.15.5.3. Channel Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2017-2033
Table 2: Global Market Volume (Units) Forecast by Region, 2017-2033
Table 3: Global Market Value (US$ Mn) Forecast by Test Type, 2017-2033
Table 4: Global Market Volume (Units) Forecast by Test Type, 2017-2033
Table 5: Global Market Value (US$ Mn) Forecast by End User, 2017-2033
Table 6: Global Market Volume (Units) Forecast by End User, 2017-2033
Table 7: North America & Europe Market Value (US$ Mn) Forecast by Country, 2017-2033
Table 8: North America & Europe Market Volume (Units) Forecast by Country, 2017-2033
Table 9: North America & Europe Market Value (US$ Mn) Forecast by Test Type, 2017-2033
Table 10: North America & Europe Market Volume (Units) Forecast by Test Type, 2017-2033
Table 11: North America & Europe Market Value (US$ Mn) Forecast by End User, 2017-2033
Table 12: North America & Europe Market Volume (Units) Forecast by End User, 2017-2033
Table 13: Latin America Market Value (US$ Mn) Forecast by Country, 2017-2033
Table 14: Latin America Market Volume (Units) Forecast by Country, 2017-2033
Table 15: Latin America Market Value (US$ Mn) Forecast by Test Type, 2017-2033
Table 16: Latin America Market Volume (Units) Forecast by Test Type, 2017-2033
Table 17: Latin America Market Value (US$ Mn) Forecast by End User, 2017-2033
Table 18: Latin America Market Volume (Units) Forecast by End User, 2017-2033
Table 19: Central America Market Value (US$ Mn) Forecast by Country, 2017-2033
Table 20: Central America Market Volume (Units) Forecast by Country, 2017-2033
Table 21: Central America Market Value (US$ Mn) Forecast by Test Type, 2017-2033
Table 22: Central America Market Volume (Units) Forecast by Test Type, 2017-2033
Table 23: Central America Market Value (US$ Mn) Forecast by End User, 2017-2033
Table 24: Central America Market Volume (Units) Forecast by End User, 2017-2033
Table 25: Caribbean Market Value (US$ Mn) Forecast by Country, 2017-2033
Table 26: Caribbean Market Volume (Units) Forecast by Country, 2017-2033
Table 27: Caribbean Market Value (US$ Mn) Forecast by Test Type, 2017-2033
Table 28: Caribbean Market Volume (Units) Forecast by Test Type, 2017-2033
Table 29: Caribbean Market Value (US$ Mn) Forecast by End User, 2017-2033
Table 30: Caribbean Market Volume (Units) Forecast by End User, 2017-2033
Table 31: South East Asia Market Value (US$ Mn) Forecast by Country, 2017-2033
Table 32: South East Asia Market Volume (Units) Forecast by Country, 2017-2033
Table 33: South East Asia Market Value (US$ Mn) Forecast by Test Type, 2017-2033
Table 34: South East Asia Market Volume (Units) Forecast by Test Type, 2017-2033
Table 35: South East Asia Market Value (US$ Mn) Forecast by End User, 2017-2033
Table 36: South East Asia Market Volume (Units) Forecast by End User, 2017-2033
Table 37: Rest of the World Market Value (US$ Mn) Forecast by Country, 2017-2033
Table 38: Rest of the World Market Volume (Units) Forecast by Country, 2017-2033
Table 39: Rest of the World Market Value (US$ Mn) Forecast by Test Type, 2017-2033
Table 40: Rest of the World Market Volume (Units) Forecast by Test Type, 2017-2033
Table 41: Rest of the World Market Value (US$ Mn) Forecast by End User, 2017-2033
Table 42: Rest of the World Market Volume (Units) Forecast by End User, 2017-2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Mn) by Test Type, 2023-2033
Figure 2: Global Market Value (US$ Mn) by End User, 2023-2033
Figure 3: Global Market Value (US$ Mn) by Region, 2023-2033
Figure 4: Global Market Value (US$ Mn) Analysis by Region, 2017-2033
Figure 5: Global Market Volume (Units) Analysis by Region, 2017-2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023-2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023-2033
Figure 8: Global Market Value (US$ Mn) Analysis by Test Type, 2017-2033
Figure 9: Global Market Volume (Units) Analysis by Test Type, 2017-2033
Figure 10: Global Market Value Share (%) and BPS Analysis by Test Type, 2023-2033
Figure 11: Global Market Y-o-Y Growth (%) Projections by Test Type, 2023-2033
Figure 12: Global Market Value (US$ Mn) Analysis by End User, 2017-2033
Figure 13: Global Market Volume (Units) Analysis by End User, 2017-2033
Figure 14: Global Market Value Share (%) and BPS Analysis by End User, 2023-2033
Figure 15: Global Market Y-o-Y Growth (%) Projections by End User, 2023-2033
Figure 16: Global Market Attractiveness by Test Type, 2023-2033
Figure 17: Global Market Attractiveness by End User, 2023-2033
Figure 18: Global Market Attractiveness by Region, 2023-2033
Figure 19: North America & Europe Market Value (US$ Mn) by Test Type, 2023-2033
Figure 20: North America & Europe Market Value (US$ Mn) by End User, 2023-2033
Figure 21: North America & Europe Market Value (US$ Mn) by Country, 2023-2033
Figure 22: North America & Europe Market Value (US$ Mn) Analysis by Country, 2017-2033
Figure 23: North America & Europe Market Volume (Units) Analysis by Country, 2017-2033
Figure 24: North America & Europe Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 25: North America & Europe Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 26: North America & Europe Market Value (US$ Mn) Analysis by Test Type, 2017-2033
Figure 27: North America & Europe Market Volume (Units) Analysis by Test Type, 2017-2033
Figure 28: North America & Europe Market Value Share (%) and BPS Analysis by Test Type, 2023-2033
Figure 29: North America & Europe Market Y-o-Y Growth (%) Projections by Test Type, 2023-2033
Figure 30: North America & Europe Market Value (US$ Mn) Analysis by End User, 2017-2033
Figure 31: North America & Europe Market Volume (Units) Analysis by End User, 2017-2033
Figure 32: North America & Europe Market Value Share (%) and BPS Analysis by End User, 2023-2033
Figure 33: North America & Europe Market Y-o-Y Growth (%) Projections by End User, 2023-2033
Figure 34: North America & Europe Market Attractiveness by Test Type, 2023-2033
Figure 35: North America & Europe Market Attractiveness by End User, 2023-2033
Figure 36: North America & Europe Market Attractiveness by Country, 2023-2033
Figure 37: Latin America Market Value (US$ Mn) by Test Type, 2023-2033
Figure 38: Latin America Market Value (US$ Mn) by End User, 2023-2033
Figure 39: Latin America Market Value (US$ Mn) by Country, 2023-2033
Figure 40: Latin America Market Value (US$ Mn) Analysis by Country, 2017-2033
Figure 41: Latin America Market Volume (Units) Analysis by Country, 2017-2033
Figure 42: Latin America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 43: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 44: Latin America Market Value (US$ Mn) Analysis by Test Type, 2017-2033
Figure 45: Latin America Market Volume (Units) Analysis by Test Type, 2017-2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Test Type, 2023-2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Test Type, 2023-2033
Figure 48: Latin America Market Value (US$ Mn) Analysis by End User, 2017-2033
Figure 49: Latin America Market Volume (Units) Analysis by End User, 2017-2033
Figure 50: Latin America Market Value Share (%) and BPS Analysis by End User, 2023-2033
Figure 51: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023-2033
Figure 52: Latin America Market Attractiveness by Test Type, 2023-2033
Figure 53: Latin America Market Attractiveness by End User, 2023-2033
Figure 54: Latin America Market Attractiveness by Country, 2023-2033
Figure 55: Central America Market Value (US$ Mn) by Test Type, 2023-2033
Figure 56: Central America Market Value (US$ Mn) by End User, 2023-2033
Figure 57: Central America Market Value (US$ Mn) by Country, 2023-2033
Figure 58: Central America Market Value (US$ Mn) Analysis by Country, 2017-2033
Figure 59: Central America Market Volume (Units) Analysis by Country, 2017-2033
Figure 60: Central America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 61: Central America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 62: Central America Market Value (US$ Mn) Analysis by Test Type, 2017-2033
Figure 63: Central America Market Volume (Units) Analysis by Test Type, 2017-2033
Figure 64: Central America Market Value Share (%) and BPS Analysis by Test Type, 2023-2033
Figure 65: Central America Market Y-o-Y Growth (%) Projections by Test Type, 2023-2033
Figure 66: Central America Market Value (US$ Mn) Analysis by End User, 2017-2033
Figure 67: Central America Market Volume (Units) Analysis by End User, 2017-2033
Figure 68: Central America Market Value Share (%) and BPS Analysis by End User, 2023-2033
Figure 69: Central America Market Y-o-Y Growth (%) Projections by End User, 2023-2033
Figure 70: Central America Market Attractiveness by Test Type, 2023-2033
Figure 71: Central America Market Attractiveness by End User, 2023-2033
Figure 72: Central America Market Attractiveness by Country, 2023-2033
Figure 73: Caribbean Market Value (US$ Mn) by Test Type, 2023-2033
Figure 74: Caribbean Market Value (US$ Mn) by End User, 2023-2033
Figure 75: Caribbean Market Value (US$ Mn) by Country, 2023-2033
Figure 76: Caribbean Market Value (US$ Mn) Analysis by Country, 2017-2033
Figure 77: Caribbean Market Volume (Units) Analysis by Country, 2017-2033
Figure 78: Caribbean Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 79: Caribbean Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 80: Caribbean Market Value (US$ Mn) Analysis by Test Type, 2017-2033
Figure 81: Caribbean Market Volume (Units) Analysis by Test Type, 2017-2033
Figure 82: Caribbean Market Value Share (%) and BPS Analysis by Test Type, 2023-2033
Figure 83: Caribbean Market Y-o-Y Growth (%) Projections by Test Type, 2023-2033
Figure 84: Caribbean Market Value (US$ Mn) Analysis by End User, 2017-2033
Figure 85: Caribbean Market Volume (Units) Analysis by End User, 2017-2033
Figure 86: Caribbean Market Value Share (%) and BPS Analysis by End User, 2023-2033
Figure 87: Caribbean Market Y-o-Y Growth (%) Projections by End User, 2023-2033
Figure 88: Caribbean Market Attractiveness by Test Type, 2023-2033
Figure 89: Caribbean Market Attractiveness by End User, 2023-2033
Figure 90: Caribbean Market Attractiveness by Country, 2023-2033
Figure 91: South East Asia Market Value (US$ Mn) by Test Type, 2023-2033
Figure 92: South East Asia Market Value (US$ Mn) by End User, 2023-2033
Figure 93: South East Asia Market Value (US$ Mn) by Country, 2023-2033
Figure 94: South East Asia Market Value (US$ Mn) Analysis by Country, 2017-2033
Figure 95: South East Asia Market Volume (Units) Analysis by Country, 2017-2033
Figure 96: South East Asia Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 97: South East Asia Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 98: South East Asia Market Value (US$ Mn) Analysis by Test Type, 2017-2033
Figure 99: South East Asia Market Volume (Units) Analysis by Test Type, 2017-2033
Figure 100: South East Asia Market Value Share (%) and BPS Analysis by Test Type, 2023-2033
Figure 101: South East Asia Market Y-o-Y Growth (%) Projections by Test Type, 2023-2033
Figure 102: South East Asia Market Value (US$ Mn) Analysis by End User, 2017-2033
Figure 103: South East Asia Market Volume (Units) Analysis by End User, 2017-2033
Figure 104: South East Asia Market Value Share (%) and BPS Analysis by End User, 2023-2033
Figure 105: South East Asia Market Y-o-Y Growth (%) Projections by End User, 2023-2033
Figure 106: South East Asia Market Attractiveness by Test Type, 2023-2033
Figure 107: South East Asia Market Attractiveness by End User, 2023-2033
Figure 108: South East Asia Market Attractiveness by Country, 2023-2033
Figure 109: Rest of the World Market Value (US$ Mn) by Test Type, 2023-2033
Figure 110: Rest of the World Market Value (US$ Mn) by End User, 2023-2033
Figure 111: Rest of the World Market Value (US$ Mn) by Country, 2023-2033
Figure 112: Rest of the World Market Value (US$ Mn) Analysis by Country, 2017-2033
Figure 113: Rest of the World Market Volume (Units) Analysis by Country, 2017-2033
Figure 114: Rest of the World Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 115: Rest of the World Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 116: Rest of the World Market Value (US$ Mn) Analysis by Test Type, 2017-2033
Figure 117: Rest of the World Market Volume (Units) Analysis by Test Type, 2017-2033
Figure 118: Rest of the World Market Value Share (%) and BPS Analysis by Test Type, 2023-2033
Figure 119: Rest of the World Market Y-o-Y Growth (%) Projections by Test Type, 2023-2033
Figure 120: Rest of the World Market Value (US$ Mn) Analysis by End User, 2017-2033
Figure 121: Rest of the World Market Volume (Units) Analysis by End User, 2017-2033
Figure 122: Rest of the World Market Value Share (%) and BPS Analysis by End User, 2023-2033
Figure 123: Rest of the World Market Y-o-Y Growth (%) Projections by End User, 2023-2033
Figure 124: Rest of the World Market Attractiveness by Test Type, 2023-2033
Figure 125: Rest of the World Market Attractiveness by End User, 2023-2033
Figure 126: Rest of the World Market Attractiveness by Country, 2023-2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
